Equities research analysts predict that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will report earnings of $0.62 per share for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Endo International’s earnings, with the highest EPS estimate coming in at $0.70 and the lowest estimate coming in at $0.55. Endo International posted earnings per share of $1.77 during the same quarter last year, which suggests a negative year-over-year growth rate of 65%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Endo International will report full year earnings of $3.67 per share for the current year, with EPS estimates ranging from $3.63 to $3.77. For the next financial year, analysts anticipate that the business will post earnings of $3.01 per share, with EPS estimates ranging from $2.55 to $3.80. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, November 9th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.85 by $0.06. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The company had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. During the same period last year, the company earned $1.01 EPS. Endo International’s revenue for the quarter was down 11.0% on a year-over-year basis.

Several research analysts have issued reports on ENDP shares. ValuEngine cut Endo International from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Zacks Investment Research raised Endo International from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research report on Wednesday, October 11th. Mizuho reissued a “buy” rating on shares of Endo International in a research report on Friday, November 10th. Cantor Fitzgerald set a $9.00 price objective on Endo International and gave the company a “hold” rating in a research report on Monday, October 30th. Finally, Royal Bank of Canada lowered their price objective on Endo International from $9.00 to $8.00 and set a “sector perform” rating on the stock in a research report on Friday, November 10th. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $11.48.

A number of hedge funds and other institutional investors have recently bought and sold shares of ENDP. Blair William & Co. IL purchased a new position in Endo International in the 2nd quarter worth approximately $126,000. LMR Partners LLP purchased a new position in Endo International in the 3rd quarter worth approximately $148,000. Point View Wealth Management Inc. lifted its holdings in Endo International by 16.6% in the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after purchasing an additional 1,900 shares in the last quarter. Riverhead Capital Management LLC lifted its holdings in Endo International by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after purchasing an additional 5,887 shares in the last quarter. Finally, Bank of Hawaii purchased a new position in Endo International in the 2nd quarter worth approximately $180,000. 93.17% of the stock is currently owned by institutional investors.

Shares of Endo International (ENDP) opened at $8.00 on Friday. The company has a market capitalization of $1,744.08, a PE ratio of 1.61, a P/E/G ratio of 2.13 and a beta of 0.59. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. Endo International has a twelve month low of $5.77 and a twelve month high of $17.99.

TRADEMARK VIOLATION NOTICE: “Endo International PLC (ENDP) Expected to Post Earnings of $0.62 Per Share” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/17/endo-international-plc-endp-expected-to-post-earnings-of-0-62-per-share.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.